Rigor, control of bias, and transparency of reporting are important for all research, and can significantly affect the quality of studies that provide the basis for large-scale therapy development programs and ultimately for clinical trials. Several disease-focused groups have provided guidance for preclinical studies involving specific neurological diseases. However, given the range of diseases within the NINDS mission and the breadth of methods used in discovery science, early translational research, and trial-enabling safety and efficacy studies, no single set of criteria can apply to all studies. Nevertheless, attention to principles of good study design and reporting transparency are essential to enable the scientific community to assess the quality of scientific findings and for peer reviewers to advise NINDS appropriately on funding decisions.
Notice: Improving the Quality of NINDS-Supported Preclinical and Clinical Research through Rigorous Study Design and Transparent Reporting: NINDS Notice NOT-NS-023
Optimizing the Predictive Value of Preclinical Research: Workshop Summary (Archived)